SCHEMBL6824120

SCHEMBL6824120

CC(C)[C@@H](N)P(=O)(OCc1ccccc1)OC(CCCCNC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DPP8 Q6V1X1 2/20 0.51
▸ DPP7 Q9UHL4 2/20 0.51
▸ SLC1A3 P43003 1/20 0.49
▸ SLC1A1 P43005 1/20 0.49
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ FOLH1 Q04609 4/20 0.48
▸ DPP4 P27487 1/20 0.48
▸ DPP9 Q86TI2 1/20 0.48
▸ CPB1 P15086 1/20 0.47
▸ CPB2 Q96IY4 1/20 0.47
▸ ANPEP P15144 1/20 0.47
▸ HTT P42858 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ MMP9 P14780 1/20 0.46
▸ TGM2 P21980 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824125 1.00 DPP8 (0.51) DPP8DPP7SLC1A3SLC1A1CA1
SCHEMBL6827321 0.82 FOLH1 (0.47) CA1CA2FOLH1CPB1CPB2
SCHEMBL6827330 0.82 FOLH1 (0.47) CA1CA2FOLH1CPB1CPB2
SCHEMBL6827235 0.82 FOLH1 (0.46) DPP8DPP7CA1CA2FOLH1
SCHEMBL6827237 0.82 FOLH1 (0.46) DPP8DPP7CA1CA2FOLH1
SCHEMBL6827234 0.81 CTSD (0.42) DPP8DPP7CA1CA2FOLH1
SCHEMBL6827227 0.81 CTSD (0.42) DPP8DPP7CA1CA2FOLH1
SCHEMBL6829507 0.79 ELANE (0.42) DPP8DPP7CA1CA2FOLH1
SCHEMBL6829510 0.79 ELANE (0.42) DPP8DPP7CA1CA2FOLH1
SCHEMBL24845248 0.78 DPP8 (0.63) DPP8DPP7SLC1A3SLC1A1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6737416-B2 THROMBOLYTIC AGENT HAVING HIGHER SAFETY MEIJI SEIKA KAISHA LTD. (JP) 2004-05-18 — — US disclosed
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2003-06-26 — — US disclosed
US-6576627-B1 Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease MEIJI SEIKA KAISHA LTD. (JP) 2003-06-10 — — US disclosed
EP-1152004-B1 Phosphonic acid derivatives having carboxypeptidase B inhibitory action MEIJI SEIKA KAISHA (JP) 2003-05-07 — — EP disclosed
EP-1174434-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B MEIJI SEIKA KAISHA LTD. (JP) 2002-01-23 — — EP disclosed
EP-1152004-A1 PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY MEIJI SEIKA KAISHA LTD. (JP) 2001-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119787-A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B CPB1, RNPEP, CPN1 DPP8 137/4885DPP7 22/4885SLC1A3 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback